VRTX

VRTX Stock-Based Compensation

$689.10MTTM · USD

Period ending:

VRTX FY Stock-Based CompUSD
VRTX FY Stock-Based Comp1991-12-31: $0.001992-12-31: $0.001993-12-31: $0.001994-12-31: $0.001995-12-31: $0.001996-12-31: $0.001997-12-31: $0.001998-12-31: $0.001999-12-31: $0.002000-12-31: $0.002001-12-31: $0.002002-12-31: $1.50M2003-12-31: $3.15M2004-12-31: $4.17M2005-12-31: $7.53M2006-12-31: $39.14M2007-12-31: $59.41M2008-12-31: $63.01M2009-12-31: $86.72M2010-12-31: $97.68M2011-12-31: $126.75M2012-12-31: $114.29M2013-12-31: $127.30M2014-12-31: $177.54M2015-12-31: $231.03M2016-12-31: $237.71M2017-12-31: $290.74M2018-12-31: $325.05M2019-12-31: $360.49M2020-12-31: $429.50M2021-12-31: $441.40M2022-12-31: $491.30M2023-12-31: $581.20M2024-12-31: $698.50M2025-12-31: $685.90M$698.50M$0.00
1991-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

VRTX stock-based compensation history

Non-cash compensation expense paid in equity. The available annual fiscal periods series contains 35 observations from Dec 31, 1991 to Dec 31, 2025.

Vertex Pharmaceuticals Stock-Based Compensation — Annual fiscal periods (USD)
Period endingStock-Based Compensation (USD)
685,900,000
698,500,000
581,200,000
491,300,000
441,400,000
429,500,000
360,489,000
325,047,000
290,736,000
237,705,000
231,025,000
177,542,000
127,303,000
114,285,000
126,751,000
97,676,000
86,722,000
63,012,000
59,407,000
39,137,000
7,530,000
4,165,000
3,146,000
1,501,000
0
0
0
0
0
0
0
0
0
0
0

Compare stock-based compensation

All VRTX financial metrics · VRTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.